Moderna is backing this micro-cap stock

January 06, 2023

Together with

 

Good day, 360 –

Here are our top 3 trade ideas today – these setups look primed! Be the best prepared trader on the Street!

CTMX - Up over 70% after announcing strategic collaboration with Moderna

WWE - 8% higher after reports Vince McMahon to return and pursue potential sale of company

HKD - Trades over 500% higher in 2 days on no news

A MESSAGE FROM MARLOW*

The Pillow for Side Sleepers

The ideal sleeping position is on the side, but without the proper support, a good morning is not in the forecast. With an adjustable design, the Marlow Pillow adapts to give side sleepers the support they need. It's made with a proprietary fill of memory foam and polyester fiber made using NASA technology and a unique zippered design for easy adjustability, allowing users to find the exact loft profile that fits them.

At the same time, cooling-infused memory foam and ventilated zipper gussets help create better airflow and regulate your body temperature, so you stay cool during the night, while its antimicrobial shell repels unwelcome guests like dust mites and bacteria.

The pillow has been perfected over eight years with numerous research, surveys, and prototypes, but to ensure satisfaction, it's also backed by Brooklinen's best-in-class customer service and a risk-free warranty.

CTMX - Up over 70% after announcing strategic collaboration with Moderna

CytomX Therapeutics announced a strategic research collaboration for mRNA-based therapies for oncology and non-oncology conditions. The collaboration will combine Moderna’s mRNA technology with CytomX’s Probody Platform.

CytomX is to receive $35 million upfront payment with the potential additional research, milestone and royalty payments.

Given that CTMX only had a market cap of around $116 million according to Finviz, this award is substantial given the current value of the company.

$3.29 was the after-hours high and should be an important pivot level today.

Above it the next potential resistance levels are $3.60-$3.70 area, $4, $4.30, $4.60 and then a gap to fill at $6.45. The stock was trading between $7 and $8 for most of 2021 so these targets are not unreasonable.

Below $3.29 there is potential support at $3, $2.80, $2.40, $2 and then a gap to fill all the way to yesterday’s close at $1.80.

WWE - 8% higher after reports Vince McMahon to return and pursue potential sale of company

Former WWE Chief Vince MacMahon plans to return to the World Wrestling Federation after leaving the company in July of 2020 on reports of sexual misconduct.

In a letter McMahon wrote that he thought there was a small window to start a sales process since WWE’s media rights are about to be renegotiated, reported the Wall Street Journal.

The Board welcomed the idea of working with McMahon on a review process but rejected the idea of his return calling the move against the interest of shareholders.

$79.60 was a major resistance level from October and is where the stock has settled so far in pre-market.

Above it the next target would be the 52-week high at $81.63, with potential resistance at $83.30 and $85.70 above that.

Below $79.60 potential targets to the downside are $77.50, $76.50, $75 and $74 with a gap to fill at yesterday’s close of $72.04.

HKD - Trades over 500% higher in 2 days on no news

AMTD Digital (HKD) traded over 200% higher yesterday and then over another 100% this morning in the pre-market on no news. This was one of the biggest pump and dumps in recent memory when the stock ran 200 times (i.e. over 20,000%) in just a few weeks in July and August of 2022. It fell from a high of over $2,500 back down to $10 before this recent flurry of buying.

There should be plenty of short-term trading setups here today, however in a stock like this stringent risk management is paramount.

The pre-market high was $68.95 this morning so that will be a major target for the bulls.

If it can trade above that, the next big psychological level is $100. Above that round numbers are worth looking at for potential resistance such as $120, $150 or $200. There is no telling when this might top out until it does.

To the downside, potential support levels are $37.50, $28 and $16.50, with a gap to fill at $10.

Economic Calendar (ET)

8:30am Employment Report

10:00am Non-Mfg PMI

10:00am Factory Orders

1:00pm Baker Hughes Rig Count

Top Headlines

RDFN: Pending U.S. home sales dropped 32% year over year to their lowest level since at least 2015 during the four weeks ending January 1

FATE: Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

EBS: Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

LIN: Linde Buys Out Stake in One of the Largest U.S. Independent Packaged Gas Distributors

SOUTHWEST AIRLINES CO: EXPECTS TO REPORT A NET LOSS IN Q4 2022 || CO SEES Q4 2022 PRE-TAX NEGATIVE IMPACT IN RANGE OF $725 MLN TO $825 MLN

PFE: U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

DNA: Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners

ATCX: Atlas Awarded $15 Million Maximum Value Contract to Support Georgia Department of Transportation’s Railroad Safety Program

AGLE: Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency

ACOR: Acorda Therapeutics Announces New Agreement with Catalent for LongTerm Global Supply of INBRIJA®

AEHR: Aehr Receives Follow-on Production Order for FOX-XP Multi-Wafer Test and Burn-in System with Integrated Automated WaferPak Aligner from Major Silicon Carbide Semiconductor Customer

BNTX: BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030

ATHE: Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)

Natural Gas Prices Drop To 18-Month Low In New York Trading

CAT: Caterpillar Announces Investment in Lithos Energy Inc. to Further Battery Pack Development and Manufacturing

IMMX: Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached

IMNM: AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

MDGL: Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

To Your Success!

 

 

62 Calef Hwy #233 Lee, New Hampshire 03861 United States

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions

 

DISCLAIMER: To more fully understand RagingBull.com, LLC’s issuer-paid advertisement disclaimer and disclosure policy located at https://ragingbull.com/paid-advertisement-disclaimer/.

ISSUER-PAID ADVERTISEMENT: This Issuer has paid RagingBull.com, LLC (“Raging Bull”) to run advertisements enhancing public awareness of the company. Raging Bull is currently invested in this company.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. Raging Bull strongly recommends you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this Advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Investing in the private companies discussed in this Advertisement is highly risky. There is currently no market for trading or liquidating the securities discussed in this Advertisement and there is no guarantee that a market will develop in the future. Readers of this Advertisement bear responsibility for their own investment research and decisions and should use information from this Advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money INVESTING OR trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Raging Bull nor any of its owners, employees OR INDEPENDENT CONTRACTORS is CURRENTLY registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements.In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.

Reply

or to participate.